Nathan Ajiashvili, Co-Chair of the New York Corporate Department, advises companies and financial institutions on a range of public and private financings, as well as domestic and foreign entities in corporate securities matters.
Mr. Ajiashvili applies a hands-on approach to help clients successfully navigate financings at every stage of their life cycles. He offers particular experience in transactions involving the life sciences industry, including the biotech and medical device/tech spaces. His work spans dozens of initial public offerings (IPOs), including a number of dual listings involving diverse jurisdictions.
Mr. Ajiashvili complements his breadth of IPO work with various types of financing transactions, such as high yield debt offerings, public and private equity offerings, leveraged buyouts, debt exchange offers, tender offers, and consent solicitations.
A trusted strategic advisor, Mr. Ajiashvili also counsels clients on general corporate and securities matters, including corporate governance issues, public company reporting obligations, and stock exchange rules and requirements.
Mr. Ajiashvili’s representative experience includes advising the issuer or underwriters in connection with securities offerings for the following companies:
- Abcam
- Achilles Therapeutics
- Aclaris Therapeutics
- Allovir
- American Well
- ATAI Life Sciences
- Avedro
- Axovant Sciences
- CureVac
- Frequency Therapeutics
- Galera Therapeutics
- Immuneering Corporation
- In8bio
- Inari Medical
- InMode
- Inspire Medical Systems
- Instil Bio
- Itamar Medical
- Keros Therapeutics
- Kiniksa Pharmaceuticals
- Landos Biopharma
- Merus
- Monte Rosa Therapeutics
- Myovant Sciences
- Outset Medical
- Oyster Point
- Pacira Pharmaceuticals
- Polypid
- Precision Biosciences
- Prevail Therapeutics
- Shattuck Labs
- Silk Road Medical
- Sol-Gel Technologies
- Spero Therapeutics
- Tela Bio
- Terns Pharmaceuticals
- Vapotherm
- VectivBio
- Verona Pharm
- Verrica Pharmaceuticals
- Vor Biopharma
- Zentalis Pharmaceuticals